statistiche ricercatore

Continente	#
EU - Europa	671
AS - Asia	633
NA - Nord America	513
Continente sconosciuto - Info sul continente non disponibili	39
AF - Africa	29
SA - Sud America	21
Totale	1.906

Nazione	#
US - Stati Uniti d'America	500
IT - Italia	338
VN - Vietnam	203
SG - Singapore	171
CN - Cina	124
DE - Germania	72
SE - Svezia	72
HK - Hong Kong	43
NL - Olanda	35
GB - Regno Unito	30
RU - Federazione Russa	30
FR - Francia	28
IN - India	21
FI - Finlandia	17
IE - Irlanda	17
BR - Brasile	11
JO - Giordania	10
CA - Canada	9
NG - Nigeria	9
TH - Thailandia	9
CI - Costa d'Avorio	8
TG - Togo	8
ID - Indonesia	6
IQ - Iraq	6
JP - Giappone	6
PL - Polonia	6
AR - Argentina	5
AT - Austria	5
BD - Bangladesh	5
KR - Corea	5
PH - Filippine	5
BE - Belgio	4
RS - Serbia	4
SA - Arabia Saudita	4
TW - Taiwan	4
ES - Italia	3
MX - Messico	3
MY - Malesia	3
EC - Ecuador	2
LT - Lituania	2
PK - Pakistan	2
PT - Portogallo	2
RO - Romania	2
TR - Turchia	2
ZA - Sudafrica	2
GE - Georgia	1
GH - Ghana	1
GR - Grecia	1
GT - Guatemala	1
GY - Guiana	1
LI - Liechtenstein	1
MK - Macedonia	1
MN - Mongolia	1
OM - Oman	1
PS - Palestinian Territory	1
PY - Paraguay	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
VE - Venezuela	1
Totale	1.867

Nome	#
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience	459
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients	231
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients	216
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma	180
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients	168
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience	158
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience	151
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia	126
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series	125
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases	92
Totale	1.906

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	164	0	8	4	19	9	11	1	13	8	27	44	20
2022/2023	247	18	32	17	33	25	12	2	22	37	11	23	15
2023/2024	140	10	9	16	9	15	9	4	9	8	22	9	20
2024/2025	524	41	46	60	39	67	43	48	34	15	56	28	47
2025/2026	670	73	43	46	49	64	39	65	19	159	57	26	30
2026/2027	37	20	17	0	0	0	0	0	0	0	0	0	0
Totale													1.906

CRIS Current Research Information System